Multiple Sclerosis Therapies Market Size, Growth, Scope, Structure, Opportunity and Forecast 2020-2025

According to IMARC Group’s latest report, titled “Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025”, the global multiple sclerosis therapies market experienced moderate growth during 2014-2019. Multiple sclerosis (MS) therapies involve the administration of injectable, infused and oral medicines, antidepressants, muscle relaxants, and physical therapy. They aid in slowing the progression of the disease and managing associated symptoms. Apart from this, they also help in controlling the heart rate and blood pressure and minimizing the frequency of relapses among patients.

Request for a PDF sample of this report: https://www.imarcgroup.com/multiple-sclerosis-therapies-market/requestsample

At present, the increasing prevalence of relapsing-remitting and secondary progressive MS across the globe represents one of the primary factors driving the market. Besides this, governing agencies of numerous countries are launching campaigns to generate awareness about the available treatments. This, along with the technological advancements, such as the introduction of innovative immunomodulators, monoclonal bodies, interferons, and immunosuppressants for the effective treatment of MS, is creating a favorable market outlook. Other factors, including considerable improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are anticipated to stimulate the growth of the market. Looking forward, IMARC Group expects the global multiple sclerosis therapies market to continue its moderate growth during the next five years.

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviors of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Competitive Landscape with Key Players:

·         Abbvie Inc.

·         Bayer Aktiengesellschaft

·         Biogen Inc.

·         Bristol-Myers Squibb Company

·         F. Hoffmann-La Roche AG (Roche Holding AG)

·         GlaxoSmithKline Plc

·         Merck & Co. Inc.

·         Novartis AG

·         Sanofi S.A.

·         Teva Pharmaceutical Industries Ltd.

Market Segmentation:

Breakup by Drug:

·      Immunomodulators

o   Copaxone

o   Avonex/Plegridy

o   Gilneya

o   Tysabri

o   Betaseron/Extavia

o   Tecifidera

o   Rebif

o   Ampyra

·      Immunosuppressants

o   Aubagio

o   Lemtrada

o   Ocrelizumab

o   Zinbryta
 

Breakup by Drug Type:

·      Biologic Drugs

·      Small Molecule Drugs
 

Breakup by Route of Administration:

·      Oral

·      Injectable

·      Intravenous
 

Breakup by Distribution Channel:

·      Hospital Pharmacies

·      Retail Pharmacies

·      Online Pharmacies

Breakup by Region:

·      North America (United States, Canada)

·      Europe (Germany, France, United Kingdom, Italy, Spain, Others)

·      Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)

·      Latin America (Brazil, Mexico, Others)

·      Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Others)

Ask Analyst for Customization and Explore full report with TOC & List of Figures: https://www.imarcgroup.com/multiple-sclerosis-therapies-market

We are updating our reports, If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.

Key highlights of the report:                                                    

• Market Performance (2014-2019)
• Market Outlook (2020-2025)
• Market Trends
• Market Drivers and Success Factors
• The Impact of COVID-19 on the Global Market
• Value Chain Analysis
• Structure of the Global Market
• Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Related Reports by IMARC Group:

Apheresis Equipment Market: https://www.imarcgroup.com/apheresis-equipment-market

Hospital Infection Therapeutics Market: https://www.imarcgroup.com/hospital-infection-therapeutics-market

Portable Medical Ventilators Market: https://www.imarcgroup.com/portable-medical-ventilators-market

Nucleic Acid Labelling Market: https://www.imarcgroup.com/nucleic-acid-labelling-market

Latin America Generic Drug Market: https://www.imarcgroup.com/latin-america-generic-drug-market

North Africa Generic Drug Market: https://www.imarcgroup.com/north-africa-generic-drug-market

West Africa Generic Drug Market: https://www.imarcgroup.com/west-africa-generic-drug-market

East Africa Generic Drug Market: https://www.imarcgroup.com/east-africa-generic-drug-market

Europe Generic Drug Market: https://www.imarcgroup.com/europe-generic-drug-market

India Minimally Invasive Surgery Market: https://www.imarcgroup.com/india-minimally-invasive-surgery-market

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:

IMARC Group

30 N Gould St Ste R

Sheridan, WY 82801 USA - Wyoming

Email: Sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

Americas: - +1 631 791 1145 | Africa and Europe: - +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800